Related Experiment Video
Updated: Sep 13, 2025
Measurement of Heart Contractility in Isolated Adult Human Primary Cardiomyocytes
Published on: August 9, 2022
Pharmacogenomics in cardiac therapy: Personalizing treatment for heart health
Niloofar Naderi1, Amir Ghaffari Jolfayi2, Amir Azimi2
1Cardiogenetic Research Center, Rajaie Cardiovascular Institute, Tehran, Iran.
Insights
Genetics significantly impacts cardiovascular diseases (CVDs), influencing conditions like cardiomyopathies and arrhythmias. Understanding genetic factors enables personalized medicine and tailored treatments for better patient outcomes.
Area of Science:
- Cardiovascular Medicine
- Human Genetics
- Pharmacogenomics
Background:
- Cardiovascular diseases (CVDs) represent a major global health burden, contributing significantly to morbidity and mortality.
- Genetic factors, encompassing both monogenic and polygenic influences, are integral to the development of various CVDs, including cardiomyopathies, aortopathies, dyslipidemias, and arrhythmias.
- These genetic predispositions are often linked to life-threatening events such as sudden cardiac death (SCD) in adults, highlighting the need for early detection and intervention.
Purpose of the Study:
- To explore the critical role of genetics and pharmacogenetics in cardiovascular medicine.
- To elucidate how genetic insights can enhance risk stratification for cardiovascular conditions.
- To examine the application of genetic information in guiding therapeutic strategies for cardiovascular diseases.
Main Methods:
- Review of current literature on genetic and pharmacogenetic influences in cardiovascular medicine.
- Analysis of how genetic screening and diagnosis facilitate timely interventions for individuals and families.
- Examination of advances in molecular genetics and pharmacogenomics for personalized cardiovascular treatment.
Main Results:
- Genetic factors are key determinants in the development of diverse cardiovascular conditions, including cardiomyopathies, arrhythmias, and dyslipidemias.
- Early genetic screening and diagnosis are crucial for timely interventions, benefiting both affected individuals and at-risk family members.
- Pharmacogenomic advances allow for tailored drug selection and dosing based on individual genetic profiles, enabling personalized cardiovascular therapies.
Conclusions:
- Genetic insights are transforming cardiovascular medicine, improving risk stratification and guiding personalized therapeutic interventions.
- Pharmacogenetic considerations are vital for optimizing the use of various cardiovascular medications, including anticoagulants, antiplatelets, and lipid-lowering therapies.
- Implementing personalized clinical interventions based on genetic information is essential for achieving optimal patient care and outcomes in cardiovascular medicine.
Abstract:
Cardiovascular diseases (CVDs) are a leading cause of morbidity and mortality worldwide. Genetics factors play a significant role in the development of CVDs, which may result from monogenic or polygenic influences. These genetic contributions can lead to various life-threatening conditions such as cardiomyopathies, aortopathies, dyslipidemias, and arrhythmias, many of which are associated with sudden cardiac death (SCD) in adults. Early genetic screening and diagnosis enable timely intervention, not only for affected individuals but also for at-risk family members. Advances in molecular genetics and pharmacogenomic are transforming the management of cardiovascular diseases. By identifying genetic variants that influence drug metabolism, clinicians can tailor drug selection and dosing to individual patients, paving the way for personalized treatment strategies. This review will explore the role of genetics and pharmacogenetics in cardiovascular medicine, with a focus on how genetic insights inform risk stratification and guide therapy. In particular, the review will examine the pharmacogenetic considerations in the use of anticoagulant, antiplatelet agents, lipid-lowering therapies, direct-acting vasodilators, antiarrhythmics, renin-angiotensin system inhibitors, and diuretics ultimately supporting the implementation of personalized clinical interventions to achieve optimal patient care outcomes.
More Related Videos
08:29A Cardiac Microphysiological System for Studying Ca2+ Propagation via Non-genetic Optical Stimulation
Published on: March 21, 2025
10:30Technical Applications of Microelectrode Array and Patch Clamp Recordings on Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes
Published on: August 4, 2022
Related Concept Videos
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:26Heart Failure Drugs: Inotropic Agents
01:29Cardiomyopathy V: Interprofessional Care
01:29Pathophysiology of Cardiac Performance
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:15Chronopharmacokinetics: Circadian Rhythms and Influence on Drug Response
The time of drug administration is an important factor to consider, as it can influence the toxic dose of a drug. For example, a study conducted by Prins et al. in 1997 examined the effects of the timing of...